CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues

British Journal of Cancer

Volumn 80, Issue 3-4, 1999, Pages 364-370

  Guichard, S ^a   Terret, C ^a   Hennebelle, I ^a   Lochon, I ^a   Chevreau, P ^b   Fretigny E ^c   Selves, J ^d   Chatelut, E ^a,e   Bugat, R ^a,e   Canal, P ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b Clinique du Parc   (France)

^c Clinique Sarrus   (France)

^d CHU PURPAN   (France)

^e UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLESTERASE; DNA TOPOISOMERASE; IRINOTECAN; PRODRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG METABOLISM; DRUG TUMOR LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARBOXYLIC ESTER HYDROLASES; COLON; COLONIC NEOPLASMS; DNA TOPOISOMERASES, TYPE I; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; RECTAL NEOPLASMS;

EID: 0032926512     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690364     Document Type: Article

References (43)

1. Benedetti P, Fiorani P. Capuani L and Wang JC (1993) Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. Cancer Res 53: 4343-4348
2. Bradford MM (1976) A rapid and sensitive method for quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254
3. Bronstein IB, Vorobyev S, Timofeev A, Jolles CJ, Alder SI and Holden JA (1996) Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies. Oncol Res 8: 17-25
4. Codegoni AM, Castagna S, Mangioni C, Scovassi AI, Broggini M and D'Incalci M (1998) DNA-topoisomerase I activity and content in epithelial ovarian cancer. Ann Oncol 9: 313-319
5. Cornarotti M. Capranico G, Bohm S, Oriana S, Spatti GB, Mariani L, Ballabio G and Zunino F (1996) Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Int J Cancer 61: 479-484
6. Creemers GJ, Lund B and Verweij J (1994) Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treat Rev 20: 73-96
7. Danks MK, Morton CL, Pawlik CA and Potter PM (1998) Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11. Cancer Res 58: 20-22
8. Deffie AM, Batra JK and Goldenberg GJ (1989) Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res 49: 58-62
9. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R and Potmesil M (1989) DNA topoisomerase 1-targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046-1048
10. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE and Ratain MJ (1994) Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54: 3723-3725
11. Haaz MC. Rivory L, Riché C, Vernillet L and Robert J (1998) Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res 58: 468-472
12. Hosokawa M, Maki T and Satoh T (1990) Characterization of molecular species of liver microsomal carboxylesterases of several animal species and humans. Arch Biochem Biophys 277: 219-227
13. Husain I, Mohler JL, Seigler HF and Besterman JM (1994) Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 54: 539-546
14. Jansen WJM, Zwart B, Hulscher STM, Giaccone G, Pinedo HM and Boven, E (1997) CPT-11 in human colon-cancer cell lines and xenografts -characterization of cellular sensitivity determinants. Int J Cancer 70: 335-340
15. Jaxel C, Kohn KW, Wani MC, Wall ME and Pommier Y (1989) Structure-activity study of the action of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and relation to antitumor activity. Cancer Res 49: 1465-1469
16. Kawato Y, Furuta T, Aonuma M, Yasuoka M, Yokokura T and Matsumoto K (1991) Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 28: 192-198
17. Knab AM, Fertala J and Bjornsti MA (1993) Mechanisms of camptothecin resistance in yeast DNA topoisomerase I mutants. J Biol Chem 268: 22322-22330
18. Kojima A, Hackett NR, Ohwada A and Crystal RG (1998) In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors. J Clin Invest 101: 1789-1796
19. Kunimoto T, Nitta K, Tanaka T, Uchara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T and Mutai M (1987) Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47: 5944-5947
20. Lund-Pero M, Jeppson B and Pero R (1994) Reduced non-specific steroidal esterase activity in human malignant tumor tissue from liver, colon and breast when compared to peritumoral and normal tissue levels. Anticancer Res 14: 2747-2754
21. McKay JA, Murray GI, Weaver RJ, Even SWB, Melvin WT and Burke MD (1993) Xenobiotic metabolising enzyme expression in colonic neoplasia. Gut 34: 1234-1239
22. McLeod HL, Douglas F, Oates M, Symonds RP, Prakash D, van der Zee AG, Kaye, SB, Brown R and Keith WN (1994) Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int J Cancer 59: 607-611
23. Massaad L, de Waziers I, Ribrag V, Janot F, Beaune PH, Morizet J, Gouyette A and Chabot GG (1993) Comparison of mouse and human colon tumors with regard to phase I and phase II drug-metabolizing enzyme systems. Cancer Res 52: 6567-6575
24. Miller SB, Main AR and Rush RS (1980) Purification and physical properties of oligomeric and monomeric carboxylesterases from rabbit liver. J Biol Chem 255: 7161-7167
25. Niimi S, Nakagawa K, Sugimoto Y, Nishio K, Fujiwara Y, Yokoyama S, Terashima, Y and Saijo N (1992) Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. Cancer Res 52: 328-333
26. Ogasawara H, Nishio K, Kanzawa F, Lee YS, Funayama Y, Ohira T, Kuraishi Y, Isogai Y and Saijo N (1995) Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11. Jpn J Cancer Res 86: 124-129
27. Potmesil M, Hsiang YH, Liu LF, Bank B, Grossberg H, Kirschenbaum S, Forlenza, TJ, Penziner A, Kanganis D, Knowles D, Traganos F and Silber R (1988) Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res 48: 3537-3543
28. Rivory LP and Robert J (1994) Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. J Chromatogr B Biomed J Appl 661: 133-141
29. Rivory LP and Robert J (1995) Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol 36: 176-179
30. Rivory LP, Bowles MR, Robert J and Pond SM (1996) Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 52: 1103-1111
31. Rothenberg M, Eckardt JR, Kuhn JG, Burris HAr, Nelson J, Hilsenbeck, SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring, GL, Rinaldi DA, Schaaf LJ and Von-Hoff DD (1996) Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14, 1128-1135
32. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P and Mahjoubi M (1997) A phase II study of CPT-11 (Irinotecan) in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients treated with 5FU-based chemotherapy. J Clin Oncol 15: 251-260
33. Satoh T and Hosokawa M (1995) Molecular aspects of carboxylesterase isoforms in comparison with other esterases. Toxicol Lett 82/83: 439-455
34. Satoh T, Hosokawa M, Atsumi R, Suzuki W, Hakusui H and Nagai E (1994) Metabolic activation of CRT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull 17: 662-664
35. Slatter JG, Su P, Sams JP, Schaaf LJ and Wienkers LC (1997) Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Disp 25: 1157-1164
36. Slichenmyer WJ, Rowinsky EK, Donehower RC and Kaufmann SH (1993) The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85: 271-291
37. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fijimoto EK, Goeke NM, Olson BJ and Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85
38. Takano H, Kohno K, Matsuo K, Matsuda T and Kuwano M (1992) DNA topoisomerase-targeting antitumor agents and drug resistance. Anticancer Drugs 3: 323-330
39. Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T and Kamataki T (1996) Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56: 3752-3757
40. Tanizawa A, Fujimori A, Fujimori Y and Pommier Y (1994) Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86: 836-842
41. Tsuji T, Kaneda N, Kado K, Yokokura T, Yoshimoto T and Tsuru D (1991) CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobiodyn 14: 341-349
42. van Ark-Otte J, Kedde MA, van der Vijgh WJF, Dingemans A-MC, Jansen WJM, Pinedo HM, Boven E and Giaccone G (1998) Determinants of CPT-11 and SN-38 activities in human lung cancer cells. Br J Cancer 77: 2171-2176
43. van der Zee AG, de Jong S, Keith WN, Hollema H, Boonstra H and de Vries EG (1994) Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors. Cancer Res 54: 749-755